Menu

Three Ebola Cases Identified in Uganda

The cases, which spread from the outbreak in the DRC, include a five-year-old boy who died.

Jun 12, 2019
Kerry Grens

ABOVE: © ISTOCK.COM, PETERHERMESFURIAN

Update (June 13): NPR reports that a second patient in Uganda has died of Ebola.

Three family members represent the first cases of Ebola in the current outbreak outside of Democratic Republic of Congo. A woman and her two young grandchildren tested positive for the virus after traveling from DRC to Uganda this week, according to the Associated Press, and one of the kids, a five-year-old boy, has died. 

“This epidemic is in a truly frightening phase and shows no sign of stopping,” Jeremy Farrar, director of the Wellcome Trust global health charity, tells Reuters.

Nearly 1,400 people have died in the outbreak that began in DRC last August, making it the second-deadliest in history, after the Ebola outbreak in West Africa from 2014–2016 that killed more than 11,000 people.

According to the AP, the victim and his family members had been waiting in DRC for transport to a healthcare facility because they showed signs of Ebola, but only some of them stayed in place. The boy and a handful of other family members traveled to Uganda where he, his brother, and grandmother ended up in a hospital near the border.

“Many people are evading (border) customs and using small footpaths and it is difficult for us to follow the contacts,” Dominique Kabongo, coordinator of Ebola response teams in Kasindi, DRC, tells the AP.

Evasion of border control, a mistrust of healthcare workers, and violence in DRC has impaired efforts to contain the virus’ transmission. A spokesperson for the World Health Organization tells Reuters that five healthcare workers have been killed in violent attacks this year.

“The current cases in Uganda will be quickly contained but the failure to stop the current Ebola epidemic in DRC is simply tragic,” Ian Jones, a virologist at Reading University, tells Reuters.

A newly developed vaccine against Ebola appears to be preventing some transmission of the disease, and drug developers are testing a number of experimental therapies to treat infections. The New York Times reports that Ugandan authorities anticipated the outbreak’s spread, and 4,700 healthcare workers there have received the vaccine.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.